Source comparison
Mechanism Pathway Differences: Upstream vs Downstream Signaling
CJC-1295 (modified growth hormone-releasing hormone) binds to GHRH receptors on somatotroph cells in the anterior pituitary, amplifying cyclic AMP (cAMP) signaling that triggers GH secretion in physiological pulses. The same pattern your body uses naturally, j
This comparison does not assign a generated winner or score.
- CJC-1295 (modified growth hormone-releasing hormone) binds to GHRH receptors on somatotroph cells in the anterior pituitary, amplifying cyclic AMP (cAMP) signaling that triggers GH secretion in physiological pulses. The same pattern your body uses naturally, just amplified. Ipamorelin, a ghrelin receptor agonist (specifically the growth hormone secretagogue receptor 1a), works synergistically by stimulating GH release through a separate pathway while suppressing somatostatin, the hormone that normally inhibits GH between pulses. Together, they create higher-amplitude GH peaks without flattening the natural pulse pattern.
- IGF-1 LR3 skips the pituitary entirely. It's a synthetic analog of human IGF-1 with three amino acid substitutions. The 'Long R3' modification extends its half-life and reduces its binding affinity to IGF binding proteins (IGFBPs), which normally sequester IGF-1 in circulation and limit bioavailability. The result: IGF-1 LR3 stays active in serum 2–3 times longer than endogenous IGF-1 and reaches target tissues (skeletal muscle, cartilage, bone) with significantly higher free-fraction availability. This translates to potent anabolic signaling. Protein synthesis, satellite cell proliferation, glucose uptake. But at the cost of negative feedback to the hypothalamus and pituitary, which may suppress natural GH and IGF-1 production during and after use.
- Our team has reviewed research protocols where combining CJC-1295 no DAC with Ipamorelin maintained baseline morning GH levels even after 12 weeks of use. The pulsatile pattern preserved endogenous function. Continuous IGF-1 LR3 administration, by contrast, showed measurable GH suppression within 4–6 weeks in multiple animal models, a suppression that persisted 2–3 weeks post-cessation.